These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35315502)

  • 1. Combined inhibition of IL‑6 and IL‑8 pathways suppresses ovarian cancer cell viability and migration and tumor growth.
    Zhang R; Roque DM; Reader J; Lin J
    Int J Oncol; 2022 May; 60(5):. PubMed ID: 35315502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer.
    Park SA; Kim LK; Park HM; Kim HJ; Heo TH
    Oncol Rep; 2022 Mar; 47(3):. PubMed ID: 35029286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in ovarian cancer cells.
    Zou M; Zhang X; Xu C
    Cell Oncol (Dordr); 2016 Feb; 39(1):47-57. PubMed ID: 26510945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells.
    Fu S; Lin J
    Anticancer Res; 2018 Nov; 38(11):6271-6279. PubMed ID: 30396947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.
    Zhang R; Wang T; Lin J
    Anticancer Res; 2021 May; 41(5):2277-2286. PubMed ID: 33952453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bazedoxifene Inhibits Cell Viability, Colony-Forming Activity, and Cell Migration in Human Non-Small Cell Lung Cancer Cells and Improves the Treatment Efficacy of Paclitaxel and Gemcitabine.
    Huang Y; Lin J; Fu X; Li L; Fu S
    Clin Respir J; 2024 Aug; 18(8):e13822. PubMed ID: 39152779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
    Wu X; Cao Y; Xiao H; Li C; Lin J
    Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
    Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
    Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.
    Ning Y; Labonte MJ; Zhang W; Bohanes PO; Gerger A; Yang D; Benhaim L; Paez D; Rosenberg DO; Nagulapalli Venkata KC; Louie SG; Petasis NA; Ladner RD; Lenz HJ
    Mol Cancer Ther; 2012 Jun; 11(6):1353-64. PubMed ID: 22391039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy.
    Wei J; Ma L; Lai YH; Zhang R; Li H; Li C; Lin J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):63. PubMed ID: 30736824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.
    Romero IL; Lee W; Mitra AK; Gordon IO; Zhao Y; Leonhardt P; Penicka CV; Mui KL; Krausz TN; Greene GL; Lengyel E
    Gynecol Oncol; 2012 Jan; 124(1):134-41. PubMed ID: 21996264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells.
    Fu S; Chen X; Lin HJ; Lin J
    Int J Oncol; 2018 Jul; 53(1):349-357. PubMed ID: 29749433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
    Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
    Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells.
    Zhang R; Chen X; Fu S; Xu L; Lin J
    Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing the selective estrogen receptor modulator
    Thilakasiri P; Huynh J; Poh AR; Tan CW; Nero TL; Tran K; Parslow AC; Afshar-Sterle S; Baloyan D; Hannan NJ; Buchert M; Scott AM; Griffin MD; Hollande F; Parker MW; Putoczki TL; Ernst M; Chand AL
    EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30885958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer.
    Fu S; Chen X; Lo HW; Lin J
    Cancer Lett; 2019 Apr; 448():11-19. PubMed ID: 30707920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
    McLean K; Tan L; Bolland DE; Coffman LG; Peterson LF; Talpaz M; Neamati N; Buckanovich RJ
    Oncogene; 2019 Feb; 38(9):1576-1584. PubMed ID: 30305729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
    Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
    Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway.
    Shang FM; Li J
    Med Clin (Barc); 2019 Jun; 152(11):425-430. PubMed ID: 30340844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.